Brevan Howard Capital Management LP Has $1.56 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Brevan Howard Capital Management LP boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 341.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,326 shares of the biopharmaceutical company’s stock after buying an additional 36,599 shares during the period. Brevan Howard Capital Management LP owned approximately 0.08% of Agios Pharmaceuticals worth $1,555,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $8,151,000. Bank of America Corp DE grew its position in Agios Pharmaceuticals by 21.6% during the fourth quarter. Bank of America Corp DE now owns 404,902 shares of the biopharmaceutical company’s stock valued at $13,305,000 after purchasing an additional 71,827 shares in the last quarter. ArrowMark Colorado Holdings LLC increased its stake in Agios Pharmaceuticals by 3.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company’s stock valued at $30,146,000 after buying an additional 34,689 shares during the period. Gallagher Fiduciary Advisors LLC lifted its position in Agios Pharmaceuticals by 7.6% in the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 788 shares in the last quarter. Finally, Caligan Partners LP boosted its stake in shares of Agios Pharmaceuticals by 8.0% during the 4th quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company’s stock valued at $20,580,000 after buying an additional 46,563 shares during the period.

Agios Pharmaceuticals Stock Down 5.4 %

Shares of AGIO stock opened at $28.34 on Wednesday. The business’s 50 day moving average is $29.60 and its two-hundred day moving average is $37.58. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The company has a market cap of $1.64 billion, a PE ratio of 2.50 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. As a group, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AGIO has been the topic of a number of research reports. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 1st. Scotiabank cut their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research note on Friday, May 2nd. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $56.00.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business’s stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company’s stock, valued at approximately $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.